Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) Invested Capital (2019 - 2025)

aTYR PHARMA's Invested Capital history spans 7 years, with the latest figure at $67.5 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 3.63% year-over-year to $67.5 million; the TTM value through Dec 2025 reached $67.5 million, down 3.63%, while the annual FY2025 figure was $67.5 million, 3.63% down from the prior year.
  • Invested Capital reached $67.5 million in Q4 2025 per ATYR's latest filing, down from $80.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $117.4 million in Q3 2021 to a low of $40.8 million in Q2 2021.
  • Average Invested Capital over 5 years is $82.6 million, with a median of $80.8 million recorded in 2024.
  • Peak YoY movement for Invested Capital: soared 246.61% in 2021, then tumbled 34.68% in 2022.
  • A 5-year view of Invested Capital shows it stood at $109.1 million in 2021, then crashed by 34.68% to $71.3 million in 2022, then rose by 26.91% to $90.5 million in 2023, then decreased by 22.61% to $70.0 million in 2024, then dropped by 3.63% to $67.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Invested Capital are $67.5 million (Q4 2025), $80.2 million (Q3 2025), and $74.7 million (Q2 2025).